Concerns about cancer risks prompted a negative vote by an FDA advisory committee on the SGLT2 inhibitor dapagliflozin, but experts remain hopeful for the novel class of antidiabetic drugs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition
Scientific Reports Open Access 17 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Jones, D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 10, 645–646 (2011). https://doi.org/10.1038/nrd3546
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3546
This article is cited by
-
SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes
Drug Safety (2024)
-
Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition
Scientific Reports (2017)
-
Chances and risks of SGLT2 inhibitors
Naunyn-Schmiedeberg's Archives of Pharmacology (2012)